Heart disease has been treated for decades with a familiar playbook: medicines to manage risk factors and invasive procedures like stents or bypass surgery when arteries become dangerously blocked. While these approaches save countless lives, cardiology is slowly entering a new chapter. The one that places non-invasive therapies at the forefront. Among these, Enhanced External Counterpulsation (EECP) stands out as a therapy that is being rediscovered. It’s not a new invention, yet today many cardiologists and patients are asking the same question: Could EECP represent the future of non-invasive cardiac treatment? Why Non-Invasive Matters More Than Ever Every year, millions of people worldwide undergo cardiac interventions. While procedures are often necessary, they are not without risks of infection, complications from anaesthesia, repeat blockages, or simply the physical toll of surgery. At the same time, the profile of the average heart patient is changing : ●  ...

Across cardiovascular clinics worldwide, physicians frequently encounter a recurring narrative: patients who, despite adhering to prescribed therapies, remain burdened by breathlessness and persistent chest discomfort during routine activities. These are not outliers or critical emergencies but rather a growing cohort of individuals living with chronic, stable angina, often confronting limited treatment options outside of invasive procedures. It was in response to this widespread therapeutic gap that the Multicenter Study of Enhanced External Counterpulsation (MUST-EECP) was conceived. This pivotal trial aimed to evaluate whether a non-invasive intervention, such as EECP, could deliver measurable improvements in exercise-induced myocardial ischemia and reduce the frequency of anginal episodes, ultimately pointing toward a more patient-centric paradigm in cardiac care. Purpose and Scope of the MUST-EECP Study The MUST-EECP study was a rigorously designed, multicenter, randomized...